Table 1.

Overview of LDNs characterised by flow cytometry.

	Disease:	Disease Group LDN Markers:	Control Group:	Reference:
Identification:	Systemic Lupus Erythematosus	CD14-CD15+ PBMC	N/A	Denny et al. (25)
	Rheumatoid Arthritis	CD14- CD15+ CD10+ CD16+ PBMC	N/A	Wright et al. (30)
	Late stage Lung Cancer	CD66b+ PBMC	N/A	Shaul et al. (29)
	Mycobacterium Tuberculosis	CD14-CD15+ PBMC	N/A	Deng et al. (12)
	Malaria	CD66b+ CD15+ CD14- PBMC	N/A	Rocha et al. (18)
	Psoriasis	CD14- CD15+ CD10+ PBMC	N/A	Teague et al. (14)
	Idiopathic Inflammatory Myopathy	CD15+ CD10+ CD14- PBMC	N/A	Seto et al. (15)
	Adult Onset Still’s Disease	CD14- CD15+ CD10+ PBMC	N/A	Torres-Ruiz et al. (20)
	Asthma	CD14- CD66b+ CD16+ CD15+ PBMC	N/A	Fu et al. (33)
Phenotyping:	Systemic Lupus Erythematosus	↑CD63 ↑Arg-1	Healthy LDNs	Rahman et al. (7)
		↑CD63 ↑Arg-1 ↑Lox1 ↑CD107a ↑CD95 ↑CD273 ↑CD274	SLE NDNs
	Lung Adenocarcinoma	↑CD66b ↑CD11b ↑CD15	Adenocarcinoma NDNs*	Liu et al. (3)
	Cancer	↑CD66b ↑CD11b	Cancer NDNs	Sagiv et al. (17)
	Human Immunodeficiency Virus	↑CD66b ↑CD63 ↑CD11b ↑CD15 ↑CD33 ↓CD16 ↓Arg1	HIV NDNs*	Cloke et al. (13)
	Mycobacterium Tuberculosis	↑CD15 ↑CD33 ↑CD66b ↓CD62L	TB NDNs	Deng et al. (12)
		↑CD16	Healthy NDNs
	Laparotomy (Lavage LDN)	↑CD63 ↑CD11b ↓CD62L	Circulating NDNs	Kanamaru et al. (9)
	Psoriasis	↑CD15 ↓CD62L	Psoriatic NDNs	Teague et al. (14)
		No difference	Healthy LDNs
	Asthma	↑CD11b ↑CD66b	Asthma NDNs	Fu et al. (33)
		No difference	Healthy LDNs

^{*Experiment contains healthy control LDN but no statistical comparison with disease groups.}